Table 5.
The top 10 terms with the most frequently occurring and newest average publication year of inflammation-related research within the field of bladder cancer.
| RANK | TERM | COUNT | RANK | TERM | Average publication year |
|---|---|---|---|---|---|
| 1 | Bladder Cancer | 1306(12.21%) | 1 | Immune Checkpoint Inhibitor | 2020.02 |
| 2 | BCG | 385(3.60%) | 2 | Pembrolizumab | 2020.09 |
| 3 | Immunotherapy | 285(2.66%) | 3 | Muscle-invasive Bladder Cancer | 2020.01 |
| 4 | Cancer | 259(2.42%) | 4 | Tumor Microenvironment | 2019.05 |
| 5 | Bladder | 191(1.79%) | 5 | Overall Survival | 2019.08 |
| 6 | Prognosis | 162(1.51%) | 6 | PD-L1 | 2019.05 |
| 7 | Inflammation | 152(1.42%) | 7 | Upper Tract Urothelial Carcinoma | 2018.04 |
| 8 | Urothelial Carcinoma | 129(1.21%) | 8 | Neutrophil-to-Lymphocyte ratio | 2018.04 |
| 9 | Biomarker | 124(1.16%) | 9 | Non-Muscle-Invasive Bladder Cancer | 2018.01 |
| 10 | Apoptosis | 107(1.01%) | 10 | Biomarker | 2017.08 |
The data in the table are from VOSviewer. The percentage is the percentage of all keywords appearing in 4301 publications.